Inflazome
Monday, 19 November 2018
Byrne Wallace Shields LLP advise Inflazome Limited in relation to its €40 million Series B Financing to develop NLRP3 inflammasome inhibitors to clinical proof-of-concept. The financing was led by Forbion, with Longitude Capital and founding investors, Novartis Venture Fund and Fountain Healthcare Partners, also participating in what is understood to be one of the largest European venture capital backed financing rounds in the biotech sector this year.
The Byrne Wallace Shields LLP team who advised on this transaction were Colin Sainsbury, Partner and Head of Life Sciences, Catherine Dowling and Senior Associate, Emmet Connolly, Solicitor from the Byrne Wallace Shields LLP Corporate Team.
Click here for more information on this transaction and to view Inflazome’s press release.
